Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)

NCT02256800 is registered in ClinicalTrials.gov with Jaw-Yuan Wang, MD, PhD as lead sponsor.

NCT NCT02256800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02256800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)
Lead sponsor
Jaw-Yuan Wang, MD, PhD
Phase
Not applicable
Overall status
Completed
Start date
August 13, 2014
Completion date
November 30, 2017
Enrollment
213 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer